2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Radiation Therapy, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bone Marrow Failure Syndromes, Hemoglobinopathies, Infectious Diseases, Viral, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5735 Cytomegalovirus reactivation after BCMA CAR T-cell therapy for multiple myeloma: Incidence, risk factors, and survival impact

Seohyeon Im, MD, Jack Khouri, MD2, Utkarsh Goel, MD3, Zachary Yetmar, MD4, Faiz Anwer, MD5, Shahzad Raza, MD6, Sandra Mazzoni, DO7, Claudio Brunstein, MD, PhD8, Marcelo Pasquini, MD9, Eric Cober, MD10, Aneela Majeed, MD11
1 Cleveland Clinic Foundation, Cleveland, Ohio, United States
2 Cleveland Clinic Foundation, Cleveland, Ohio, United States
3 Cleveland Clinic Foundation, Cleveland, Ohio, United States
4 Cleveland Clinic Foundation, Cleveland, Ohio, United States
5 Cleveland Clinic Foundation, Cleveland, Ohio, United States
6 Cleveland Clinic Foundation, Cleveland, Ohio, United States
7 Cleveland Clinic Foundation, Cleveland, Ohio, United States
8 Cleveland Clinic Foundation, Cleveland, Ohio, United States
9 Cleveland Clinic Foundation, Cleveland, Ohio, United States
10 Cleveland Clinic Foundation, Cleveland, Ohio, United States
11 Cleveland Clinic Foundation, Cleveland, Ohio, United States

Background

Cytomegalovirus infection (CMVI) is common after allogeneic hematopoietic cell transplantation (alloHCT); however, its incidence and impact are less clear in patients receiving BCMA-directed CAR T-cell therapy (CAR-T) for multiple myeloma (MM). This study aimed to evaluate the incidence of and risk factors for CMVI in this population and to assess its association with overall survival (OS) and progression-free survival (PFS).

Methods

Patients who received BCMA CAR-T for MM between August 2021 and January 2024 were included. Patients with prior alloHCT, CMV-directed treatment at CAR-T infusion, or no post CAR-T CMV PCR testing were excluded. CMVI, the primary end point, was defined as any detectable CMV DNA by plasma PCR, including results below the lower limit of quantification (<35 IU/mL); the secondary end point was CMV DNA ≥200 IU/mL, each assessed through 1 year after CAR-T. Per institutional protocol, patients underwent CMV PCR at discharge and monthly thereafter for three additional samples. Corticosteroid exposure was captured through day +21; high-dose corticosteroid use was defined as ≥3 days of dexamethasone ≥10 mg/day within any 7-day window, or any administration of methylprednisolone ≥500 mg/day. Cause-specific Cox proportional hazards regression was used to identify risk factors for CMVI, and the cumulative incidence of CMVI was calculated treating death and progressive disease as competing risks. A 100-day landmark analysis evaluated the impact of early CMVI on 1-year OS and PFS.

Results

Of 103 patients screened, 93 were included in the analysis. Of these, 54 (58%) received ciltacabtagene autoleucel (cilta-cel), and 39 (42%) received idecabtagene vicleucel (ide-cel). The median number of prior lines of therapy was 5 (IQR, 4-7). High-risk cytogenetics, including 1q gain, t(4;14), t(14;16), and 17p deletion, were present in 35 (38%). Systemic bridging therapy was administered to 83 patients (89%), of whom 22 (26%) received cytotoxic chemotherapy. Lymphodepletion (LD) consisted of fludarabine/cyclophosphamide in 27 patients (29%) and bendamustine in 66 (71%).

Baseline CMV serostatus was available in all patients; 55 (59%) were CMV-seropositive. All 22 patients who developed CMVI (24% of the cohort) were seropositive, yielding an incidence of 40% among seropositive patients. The median time to CMVI was 28 days (IQR, 27-34). Four patients (4%) developed CMV DNA 200 IU/mL, and no patients developed end-organ disease. Cytokine release syndrome (CRS) occurred in 73 patients (78%), including 23 (25%) with grade ≥2, and immune effector cell–associated neurotoxicity syndrome (ICANS) in 23 (25%). A total of 55 patients (59%) received CRS/ICANS-directed treatment including tocilizumab, anakinra, or siltuximab. 16 (17%) received high-dose corticosteroids through day +21.

On univariable Cox regression, age (per year; HR, 1.07; 95% CI, 1.02-1.13) and cilta-cel use (HR, 0.27; 95% CI, 0.11-0.67) were associated with CMVI. However, cilta-cel and ide-cel were given during largely non-overlapping periods (median infusion date, July 2023 vs April 2022), and post hoc adjustment for continuous calendar time attenuated this association (HR, 0.42; 95% CI, 0.11-1.60). Prior lines ≥6, cytotoxic bridging, pre-LD absolute lymphocyte count (ALC) <0.5 ×10³/µL, high-risk cytogenetics, LD regimen, CRS (any grade or grade ≥2), ECOG ≥2, ICANS, CRS/ICANS-directed treatment, high-dose corticosteroid use, IgG <400 mg/dL, and ALC decline (per 50% decrease) were not associated with CMVI.

The cumulative incidence of CMVI at 30 and 100 days after CAR-T was 14.0% and 22.6%, respectively. In the landmark analysis, 1-year OS was 90.5% (95% CI, 67.0-97.5) in patients with CMVI by day 100 versus 91.3% (95% CI, 81.7-96.0) in those without (log-rank p=0.88). One-year PFS was 55.6% (95% CI, 30.5-74.8) versus 73.1% (95% CI, 60.8-82.1; p=0.08).

Conclusion

CMVI occurred in roughly a quarter of the patients after BCMA CAR T-cell therapy. Reactivation was confined to seropositive patients, and most cases were detected within the first two months. DNAemia ≥200 IU/mL was uncommon, with no cases of end-organ disease. Older age was the only factor associated with CMVI after accounting for era of treatment. CRS, ICANS, CRS/ICANS-directed treatment, and exposure to high-dose corticosteroids were not predictive. Targeted surveillance of CMV seropositive patients early after CAR-T is a reasonable approach.

Seohyeon Im, MD: No relevant conflicts of interest to declare.